First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry

The results of this nonrandomized, observational study suggest that first-line taxane therapy may benefit senior adults with mCRPC more than alternative therapies. Treatment decisions should not be based on chronological age.